|
Video: What is a Stock Split?
|
|
Kiora Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing products for treating disorders of the eye. Co.'s key product in clinical development is the EyeGate Ocular Bandage Gel, a topically applied eye drop formulation of modified hyaluronic acid (HA). HA is a naturally occurring polymer that is used in various physiological processes, including wound healing, hydration, tissue homeostasis, and joint lubrication. Co. modifies the HA through chemical cross-linking, which allows it to adhere to the ocular surface providing protection and lubrication for the treatment of corneal wounds, defects, and epitheliopathies. According to our KPRX split history records, Kiora Pharmaceuticals has had 1 split. | |
|
Kiora Pharmaceuticals (KPRX) has 1 split in our KPRX split history database. The split for KPRX took place on September 27, 2022. This was a 1 for 40 reverse split, meaning for each 40 shares of KPRX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 25 share position following the split.
When a company such as Kiora Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the KPRX split history from start to finish, an original position size of 1000 shares would have turned into 25 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Kiora Pharmaceuticals shares, starting with a $10,000 purchase of KPRX, presented on a split-history-adjusted basis factoring in the complete KPRX split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
02/17/2015 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$226.00 |
|
End price/share: |
$0.47 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.79% |
|
Average Annual Total Return: |
-48.92% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$20.81 |
|
Years: |
9.19 |
|
|
|
Date |
Ratio |
09/27/2022 | 1 for 40 |
|
|